Physician profile

Michael E Goldis

Geriatric Medicine (Internal Medicine) · Stratford, NJ

NPI 1982603247

$1,763.82

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $475.72 2019-2020
Glaxosmithkline, LLC. $197.23 2019-2020
Astellas Pharma US INC $128.54 2019-2020
Amarin Pharma, INC. $119.86 2019-2021
Kyowa Kirin, INC. $117.54 2020
Philips North America LLC $106.39 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $97.21 2019-2020
Avanir Pharmaceuticals, INC. $96.16 2019
Astrazeneca Pharmaceuticals Lp $68.32 2019-2020
Novartis Pharmaceuticals Corporation $57.07 2019-2020
Actelion Pharmaceuticals US, INC. $55.13 2019
Collegium Pharmaceutical, INC. $40.75 2020
Eisai INC. $40.07 2020
Mannkind Corporation $28.80 2019
Ferring Pharmaceuticals INC. $23.17 2019
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Abbvie INC. $14.99 2020
Scilex Pharmaceuticals INC. $14.78 2019
Circassia INC. $14.61 2019
Neotract INC. $14.39 2019
Teva Pharmaceuticals USA, INC. $14.07 2020
Janssen Pharmaceuticals, INC $13.80 2019
Biogen, INC. $12.94 2020
Gilead Sciences, INC. $12.28 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael E Goldis

$1,763.82

in general payments reported 2019-2025

Years
2019-2021
Top company
Sunovion Pharmaceuticals INC.

https://glasscript.com/doctor/134785/michael-e-goldis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.